Key result
The addition of a specialist heart failure prescribing pharmacist to consultant-led ward rounds accounted for 52% (n=118) of 226 suggested medicine changes, primarily driven by safety concerns.
Why the study?
There was a lack of evidence regarding the impact of specialist heart failure prescribing pharmacists attending consultant-led inpatient heart failure ward rounds.
Does the addition of a specialist heart failure prescribing pharmacist improve medication safety and optimization during consultant-led heart failure ward rounds?
Observational (n=158)
No
Does the addition of a specialist heart failure prescribing pharmacist improve medication safety and optimization during consultant-led heart failure ward rounds?
The addition of a specialist heart failure prescribing pharmacist to consultant-led ward rounds enhances medication safety and holistic optimization beyond just heart failure-specific therapies.
Answers are grounded in this paper and cite their sources.
Supports pharmacist integration into HF ward rounds for medication optimization; leaves open randomized confirmation of clinical benefits.
OBJECTIVE: Pharmacists attending general medical post-admission ward rounds is established good practice. However, there is a lack of evidence on the impact of specialist heart failure (HF) prescribing pharmacists on consultant HF ward rounds. The aim of this study was to evaluate the impact on prescribing when a specialist HF prescribing pharmacist attended inpatient HF ward rounds. METHODS: A prospective service evaluation completed at a tertiary hospital between September and December 2020. The same HF prescribing pharmacist attended the HF consultant-led ward round once a week on 15 occasions. For each medicine change, the pharmacist documented: who suggested the intervention, the medicine, prescribing action, reason for review and the primary reason for change. Medicines were categorised into four groups (heart failure, cardiovascular, anticoagulation and other) for analysis. RESULTS: A total of 158 patients were reviewed and 226 individual changes suggested; 48% of these were consultant led (n=108) and 52% (n=118) due to pharmacist recommendations. All medicines interventions were prescribed on the round by the pharmacist. For consultants, the primary reason for medicine change was to ensure efficacy of HF medicines, 80% (n=73), followed by safety (HF medicines), 20% (n=18). For the pharmacist, the primary reason was safety across all the medicine groups, 36% (n=42), followed by efficacy relating to missing drug history items, 24% (n=28). CONCLUSIONS: HF consultants focused on ensuring patients have the most effective combination of HF medications. The addition of a specialist HF prescribing pharmacist ensured a wider range of medicines were reviewed for safety and optimisation, helping to deliver a holistic review of all medications.
No takes yet. Share an insight, caveat, or question.
Campbell et al. (2021) conducted an observational in Heart failure (n=158). Specialist heart failure prescribing pharmacist attending consultant-led ward rounds was evaluated on Medicine changes and primary reason for change. The addition of a specialist heart failure prescribing pharmacist to consultant-led ward rounds accounted for 52% (n=118) of 226 suggested medicine changes, primarily driven by safety concerns.
Synapse has enriched 10 related papers. Consider them for comparative context: